Search PubMed⌕ Search

Biomedical subjects

L M Gunne

Publications and source records attributed to L M Gunne.

At least 73 records · Page 4Linked to original sources
PubMed1977

Thyrotropin-releasing hormone (TRH) inchronic schizophrenia. A controlled study.

A controlled study on the effect of synthetic Thyrotropin-Releasing Hormone (TRH) versus placebo in 10 drug-free chronic schizophrenics is presented. TRH 600 mug or placebo was administered intravenously on 4 consecutive days in a double-blind cross-over design and the schizophrenic symptoms were scored daily by use of two rating scales (CPRS and NOSIE). Blood samples were taken before and 30 and 45 minutes after the first and the fourth injection and analyzed for TSH. No changes in symptom intensity were found during the TRH or placebo treatment period and no difference was obtained between the two treatments. The dose of TRH used caused a significant increase in the plasma level of TSH which indicated a normal pituitary responsiveness to TRH. The data do not support the notion that TRH has a beneficial effect in chronic schizophrenic patients.

Adult↗
PubMed1976

Haloperidol-induced tardive dyskinesia in monkeys.

In three cebus monkeys the chronic daily administration of haloperidol (0.5 mg/kg/day orally) created sedation and parkinsonism during the first 5-7 weeks. Later the animals developed signs reminiscent of acute dystonia, as seen in the clinic during treatment with neuroleptics. These signs were dose-dependent and in extreme cases included widespread tonic and clonic seizures. After 3 and 12 months, respectively, two of the cebus monkeys developed buccolingual signs (grimacing and tongue protrusion), similar to tardive dyskinesia in the clinic. The tardive dyskinesia symptoms were reduced in a dose-dependent manner after each haloperidol administration, being most pronounced in the morning before haloperidol was given. Biperiden reduced acute dystonia but reinstated signs of tardive dyskinesia, which had been abolished by haloperidol. It is suggested that cebus monkeys may provide a useful animal model for the study of neurologic long-term complications from neuroleptic drugs.

Animals↗
PubMed1975

Disposition of methadone in methadone maintenance.

Six detoxified opiate addicts housed in a closed metabolic ward received methadone in stepwise increasing doses of 10, 20, 40, and 80 mg/day during 1 month. Four were given 14C-methadone at the lowest dose and again at the highest dose. Of the subjects receiving radiomethadone, 2 excreted the major part of the radioactivity in urine and 2 about equally in urine and feces. In addition to methadone, 7 metabolites were isolated and identified in urine and 3 metabolites in feces. About 75% of the urinary and fecal radioactive metabolites were unconjugated. Urinary excretion of methadone and its major N-monomethylated metabolite accounted for 17% to 57% of the given dose. The ratio of metabolite to parent drug increased in 5 of 6 subjects, and the urinary recovery of unchanged methadone decreased during the period. The results indicate that enhanced demethylation of methadone may occur during oral administration to man.

Adult↗